title: Caged naloxone reveals opioid signaling deactivation kinetics.
abstract: The spatiotemporal dynamics of opioid signaling in the brain remain poorly defined. Photoactivatable opioid ligands provide a means to quantitatively measure these dynamics and their underlying mechanisms in brain tissue. Although activation kinetics can be assessed using caged agonists, deactivation kinetics are obscured by slow clearance of agonist in tissue. To reveal deactivation kinetics of opioid signaling we developed a caged competitive antagonist that can be quickly photoreleased in sufficient concentrations to render agonist dissociation effectively irreversible. Carboxynitroveratryl-naloxone (CNV-NLX), a caged analog of the competitive opioid antagonist NLX, was readily synthesized from commercially available NLX in good yield and found to be devoid of antagonist activity at heterologously expressed opioid receptors. Photolysis in slices of rat locus coeruleus produced a rapid inhibition of the ionic currents evoked by multiple agonists of the μ-opioid receptor (MOR), but not of α-adrenergic receptors, which activate the same pool of ion channels. Using the high-affinity peptide agonist dermorphin, we established conditions under which light-driven deactivation rates are independent of agonist concentration and thus intrinsic to the agonist-receptor complex. Under these conditions, some MOR agonists yielded deactivation rates that are limited by G protein signaling, whereas others appeared limited by agonist dissociation. Therefore, the choice of agonist determines which feature of receptor signaling is unmasked by CNV-NLX photolysis.
authors: Howard Hughes Medical Institute, Department of Neurobiology, Harvard Medical School, Boston, Massachusetts (M.R.B., R.C.S., B.L.S.); Vollum Institute, Oregon Health & Science University, Portland, Oregon (J.T.W.); and Janelia Farm Research Campus, Howard Hughes Medical Institute, Ashburn, Virginia (L.D.L.).
authors: Matthew R
authors: MR
authors: Banghart
authors: John T
authors: JT
authors: Williams
authors: Ruchir C
authors: RC
authors: Shah
authors: Luke D
authors: LD
authors: Lavis
authors: Bernardo L
authors: BL
authors: Sabatini
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D051381:Rats; D017450:Receptors, Opioid, mu / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009270:Naloxone
references: Nature. 2006 Aug 10;442(7103):645-50
references: 16878137
references: Methods Enzymol. 2010;484:445-69
references: 21036245
references: Nature. 1998 Dec 17;396(6712):679-82
references: 9872316
references: J Neurochem. 1980 Mar;34(3):583-93
references: 6243694
references: J Biol Chem. 2009 Sep 25;284(39):26732-41
references: 19542234
references: J Neurosci. 2013 Feb 27;33(9):4118-27
references: 23447620
references: Neuron. 2012 Oct 4;76(1):22-32
references: 23040804
references: J Org Chem. 2010 Jul 2;75(13):4648-51
references: 20536152
references: Mol Pharmacol. 1994 Feb;45(2):330-4
references: 8114680
references: J Neurosci Methods. 2009 May 30;180(1):9-21
references: 19427524
references: Nature. 2012 Mar 21;485(7398):321-6
references: 22437502
references: Pharmacol Ther. 2007 Sep;115(3):410-8
references: 17655934
references: Mol Pharmacol. 2010 Oct;78(4):756-66
references: 20647394
references: Pharmacol Ther. 2003 Jun;98(3):325-54
references: 12782243
references: NIDA Res Monogr. 1998 Mar;178:440-66
references: 9686407
references: Curr Opin Neurobiol. 2003 Jun;13(3):348-53
references: 12850220
references: AAPS J. 2006 Mar 10;8(1):E126-37
references: 16584119
references: Physiol Rev. 2001 Jan;81(1):299-343
references: 11152760
references: Nature. 1998 Dec 17;396(6712):683-7
references: 9872317
references: J Neurosci. 1996 Feb 15;16(4):1479-85
references: 8778299
references: J Pharmacol Exp Ther. 1995 Jan;272(1):423-8
references: 7815359
references: Nature. 1998 Dec 17;396(6712):674-9
references: 9872315
references: J Neurosci. 1996 Oct 15;16(20):6374-85
references: 8815916
references: Mol Pharmacol. 1997 Jul;52(1):136-43
references: 9224823
references: Mol Pharmacol. 2006 Nov;70(5):1783-91
references: 16926282
references: Neuron. 2012 Jan 26;73(2):249-59
references: 22284180
references: Mol Pharmacol. 1984 Nov;26(3):489-97
references: 6092898
references: Photochem Photobiol Sci. 2012 Mar;11(3):556-63
references: 22249211